fda warning letter glp-1 october 2025 CDER Letters Jump 50% in FY — What That Means for Industry fda warning letter glp-1 october

Changes in high-density lipoprotein cholesterol with risk of Cardiovascular Disease among initially high-density lipoprotein-high participants

Lindsay KL, Brennan L, Kennelly MA, et al

The challenge is that GLP-1 medications make you not want to eat so every meal needs to deliver high protein in a portion size your reduced appetite can handle

If you fall into any of those categories and experience symptoms, seek medical care

The oral semaglutide offered through MadeMed is a compounded sublingual formulation - it is not the same product, does not use the same proprietary absorption technology, and has not been independently evaluated by the FDA for bioavailability, dosing equivalence, or absorption characteristics relative to the FDA-approved version